ENG/中
老虎證券
市场
行情
24/7新闻
产品
Cash Boost账户
期权
A股通
港股
固定票息票据
美股
ETF
基金超市
美国国债
新加坡股
期货
Tiger BOSS Debit Card
老虎钱袋子
功能
经纪人
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登入
立即註冊
Toggle
澳股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
CHIMERIC THERAPEUTICS LTD
0.006
-0.001
-14.29%
成交量:
2.14萬
成交額:
129
市值:
57.54萬
市盈率:
-0.01
高:
0.006
開:
0.006
低:
0.006
收:
0.007
52周最高:
0.400
52周最低:
0.006
股本:
9,590.64萬
流通股本:
2,907.08萬
量比:
0.03
換手率:
0.07%
股息:
- -
股息率:
- -
每股收益(TTM):
-0.610
每股收益(LYR):
-0.610
淨資產收益率:
-1290.99%
總資產收益率:
-46.75%
市淨率:
-0.07
市盈率(LYR):
-0.01
資料載入中...
總覽
公司
新聞資訊
公告
概念
沒有相關數據
資金流向
資金流入:
資金流出:
實時
日
周
月
季度
年
新聞資訊
體內通路取得進展,Chimeric Therapeutics擬與潛在合作伙伴重啓談判
美股速递
·
08/19
Chimeric Therapeutics啓動戰略評估,或出售、授權或合作其CHM CDH17資產與項目
美股速递
·
08/19
Chimeric Therapeutics Ltd實施重大成本削減措施,預計年度支出將減少約400萬澳元
美股速递
·
08/19
Chimeric Therapeutics Ltd:FY26財務報告預計將包含持續經營重大不確定性
美股速递
·
08/19
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/CHM.AU"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CHM.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CHM.AU\",,,,,undefined,":{"symbol":"CHM.AU","market":"AU","secType":"STK","nameCN":"CHIMERIC THERAPEUTICS LTD","latestPrice":0.006,"timestamp":1789452720000,"preClose":0.007,"halted":0,"volume":21448,"delay":0,"changeRate":-0.14285714285714285,"nameEN":"CHIMERIC THERAPEUTICS LTD","floatShares":29070766,"shares":95906400,"eps":-0.6097,"marketStatus":"未開盤","change":-0.001,"latestTime":"09-15 16:12:00 AEST","open":0.006,"high":0.006,"low":0.006,"amount":129,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.6097,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1789516800000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.007,"openAndCloseTimeList":[[1789430400000,1789452000000]],"volumeRatio":0.033146971772917526,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"CHM.AU","preClose":0.006,"auctionPrice":0.006,"auctionVolume":20000,"auctionTime":1789506665997,"referenceTime":1789381803089,"auction":1,"marketStatus":"盘前竞价","timestamp":1789506665997}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CHM.AU\",,,,,undefined,":{"symbol":"CHM.AU","floatShares":29070766,"roa":"-46.75%","roe":"-1290.99%","lyrEps":-0.6097,"volumeRatio":0.033146971772917526,"shares":95906400,"dividePrice":0,"high":0.006,"amplitude":0,"preClose":0.007,"low":0.006,"week52Low":0.006,"pbRate":"-0.07","psRate":"-3.03","week52High":0.4,"institutionHeld":0,"latestPrice":0.006,"eps":-0.6097,"divideRate":0,"volume":21448,"delay":0,"ttmEps":-0.6097,"open":0.006,"prevYearClose":0.2,"prevWeekClose":0.008,"prevMonthClose":0.011,"prevQuarterClose":0.065,"fiveDayClose":0.007,"twentyDayClose":0.035,"sixtyDayClose":0.068,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CHM.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2026-04-22","symbol":"CHM.AU","defaultRemindTime":1776816000000,"type":"split","dateTimestamp":1776780000000,"forFactor":100,"toFactor":1,"ratio":100}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CHM.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CHM.AU\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1133213709","title":"體內通路取得進展,Chimeric Therapeutics擬與潛在合作伙伴重啓談判","url":"https://stock-news.laohu8.com/highlight/detail?id=1133213709","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133213709?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 07:11","pubTimestamp":1787094670,"startTime":"0","endTime":"0","summary":"Chimeric Therapeutics Ltd——随着其体内通路不断推进,公司计划重新与潜在合作伙伴展开接触。\n这一动向标志着该生物制药企业在研发管线的关键节点上,正积极寻求外部协作与资源整合,以加速候选疗法的临床转化进程。\n在体内研究数据渐趋成熟的背景下,管理层显然认为,此刻正是重返谈判桌、深化战略联盟的恰当时机。无论是联合开发、授权许可,抑或是更广泛的商业合作,均有可能成为下一步棋局中的选项。\n市场观察人士指出,此类举措往往折射出企业对自身技术平台的信心增强,同时也暗示着其商业化路径正从实验室迈向更广阔的产业舞台。对于关注细胞治疗领域的投资者而言,这一信号无疑值得密切留意。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHM.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191148680","title":"Chimeric Therapeutics啓動戰略評估,或出售、授權或合作其CHM CDH17資產與項目","url":"https://stock-news.laohu8.com/highlight/detail?id=1191148680","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191148680?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 07:11","pubTimestamp":1787094668,"startTime":"0","endTime":"0","summary":"Chimeric Therapeutics(澳交所代码:CHM)宣布,已启动一项流程,旨在探索出售、对外许可或合作其CHM CDH17资产及相关项目的潜在可能。此举意味着公司正积极评估该资产在市场上的多种发展路径,以最大化其价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHM.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106385827","title":"Chimeric Therapeutics Ltd實施重大成本削減措施,預計年度支出將減少約400萬澳元","url":"https://stock-news.laohu8.com/highlight/detail?id=1106385827","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106385827?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 07:10","pubTimestamp":1787094609,"startTime":"0","endTime":"0","summary":"Chimeric Therapeutics Ltd——重大成本削减计划已正式落地,此举预计将使公司年度化支出缩减大约400万澳元。\n这家生物医药企业正积极调整运营策略,以优化财务结构。通过一系列精简措施,公司力求在维持核心研发管线推进的同时,显著降低整体资金消耗速率。\n此番成本控制动作,不仅反映了管理层对当前市场环境的审慎态度,也彰显了其提升资本效率、延长现金流跑道以支撑后续关键里程碑的决心。业界普遍认为,此类战略性节流举措,对于处于临床阶段、亟需平衡研发投入与财务稳健的生物科技公司而言,至关重要。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CHM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121509471","title":"Chimeric Therapeutics Ltd:FY26財務報告預計將包含持續經營重大不確定性","url":"https://stock-news.laohu8.com/highlight/detail?id=1121509471","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121509471?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 07:10","pubTimestamp":1787094609,"startTime":"0","endTime":"0","summary":"Chimeric Therapeutics Ltd(CHIMERIC THERAPEUTICS LTD)发布公告称,其2026财年财务报告预计将涵盖一项与持续经营相关的重大不确定性。这一消息揭示了公司在未来运营持续性方面可能面临的严峻挑战。根据公告内容,该不确定性因素的存在,可能对公司维持正常业务运作的能力构成实质性影响。投资者需密切关注这一动态,以评估公司未来的财务稳健性及可持续经营前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHM.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/CHM.AU\",params:#limit:6,delay:true,,,undefined,":[]}}